Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33410225

about

Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor Panobinostat for the treatment of multiple myeloma: the evidence to date Clinical use of proteasome inhibitors in the treatment of multiple myeloma Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy Trial Watch: Proteasomal inhibitors for anticancer therapy Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review.A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.Deacetylase inhibitors: an advance in myeloma therapy?Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Reversal of bortezomib resistance in myelodysplastic syndrome cells by MAPK inhibitors.Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2.Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.Myeloma today: Disease definitions and treatment advances.HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide Dinutuximab and Panobinostat Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis.Salvage therapy of multiple myeloma: the new generation drugs.Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Panobinostat: a review of trial results and future prospects in multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.Treatment-related symptom management in patients with multiple myeloma: a review.Panobinostat: first global approval.Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma.Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.New pharmacotherapy options for multiple myeloma.Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma.Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

P2860

Q26747768-9DB169D1-4BF6-4CA8-A9A3-E3A5AC899703 Q26778674-22703F4D-7A9E-47AC-BB25-7ABDE83BB0E1 Q28080999-87C35021-A7BF-41FC-BD0A-90AB1DB08B16 Q28082536-6450945D-7C19-4DE0-81D8-FD3F3D26873C Q28082910-578E5930-A48A-42CC-8280-5C95048BCDEF Q30802505-72E145C8-1131-4835-B2F0-025B321FC227 Q33423168-088B86EA-C391-40E5-84F3-5C0D026120DA Q33426983-B31D861A-7DE0-426A-853B-8FDF9E9AA86C Q33428098-391BCE55-EDEE-4254-91F1-B07FE8609C43 Q33429115-BF5CB442-CC60-4EE8-ADE7-E8857B4D63A1 Q33429707-672038D3-ADE4-4A74-99A6-153388DA4A7F Q33432845-145D74F4-9351-442E-97E8-EF846E6F0AD7 Q33436058-4F58FAFC-52F0-40CC-AFAB-8AA41D6C02C0 Q33438321-A71DB50B-C134-4617-B15E-71C5C9201EA5 Q33443179-2C6DF9DE-A8D2-4037-991C-3A253FE20A2E Q34602263-DC388731-C6B0-422E-AD04-6B5AEA286705 Q35114769-4EF3989B-44D1-40DC-8A51-37D1DB8EA144 Q35592352-5E46A3C1-0A67-4741-B842-E4B9290624C1 Q36301520-182E3071-F7A9-4C71-BC77-C70E0C92A05C Q36470699-D702B9CB-5ACE-41B7-9A52-0A009F89FACD Q36544516-EE722411-F594-473B-85E3-30B92F23DF7E Q36572408-6B47B138-DF48-4166-AA5E-E6207C5493E8 Q37150016-BE6F6736-2648-433C-B0A4-D38BC917B1E2 Q37199772-CC44AF78-4E74-4178-9C42-5407FF064F21 Q37439209-58772340-E084-4571-9769-827765B8C875 Q37623809-E9D76143-CE69-4918-9385-3AB7A0DA8AD5 Q37677121-B88BDE59-F18F-47F9-9B5A-830F2F832D42 Q38223433-EE1C339C-88AB-4DBD-872A-6027FE86AF3F Q38255333-122BCB5A-9679-467B-B783-247DC084845D Q38269612-A3AD4AD8-0F75-405F-8019-7634D96E9BFF Q38271032-0547DC93-D190-4F53-9A74-18343537AC8C Q38342281-2E70E61C-C8FB-4B43-8C78-2348468B6591 Q38403118-024C13E1-B32B-4546-A62C-9803B134780B Q38519497-74D4274B-1B4B-4F4B-96FC-B2B6687EB614 Q38616807-9AC90CA1-1A26-4199-996F-E1182822E8BC Q38637652-098353DC-5FE7-497F-946D-DB7C79417C4F Q38672091-54AFE3C9-41B8-4EFB-B9BB-68F1A859E71E Q38673764-3BCCDC1D-FA8E-4622-934C-5858395B9EFB Q38716460-59D3D808-56DA-4E87-9BEC-08CE39D1E1AF Q38742700-2D96CACD-10FD-4B4C-98F5-6DB199F400E2

P2860

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

http://www.wikidata.org/entity/Q33410225

description

2013 nî lūn-bûn

@nan

2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Phase Ib study of panobinostat ...... d refractory multiple myeloma.

@ast

Phase Ib study of panobinostat ...... d refractory multiple myeloma.

@en

type

label

Phase Ib study of panobinostat ...... d refractory multiple myeloma.

@ast

Phase Ib study of panobinostat ...... d refractory multiple myeloma.

@en

prefLabel

Phase Ib study of panobinostat ...... d refractory multiple myeloma.

@ast

Phase Ib study of panobinostat ...... d refractory multiple myeloma.

@en

P1433

Q33410225-A1300781-6B61-42C5-BE07-4E1D19AE03FE

P1476

Q33410225-92AC3130-AD81-4A94-ACEC-D38F7C91847C

P2093

Q33410225-035D568A-BD11-4C27-AEAB-A371107AB9BE

Q33410225-17868A1C-B322-4EC6-928E-DF65E057A18F

Q33410225-3610E186-A01E-47A9-B41F-07C2B167AEAA

Q33410225-57E40B04-A97C-48D5-ABA9-4F836504BB25

Q33410225-64185D26-B49F-4A8E-B714-B8D7333AFB95

Q33410225-66045820-0E04-45F5-AF21-630D80F23964

Q33410225-A6B1C897-6391-4683-95C9-3E76A9FDA252

Q33410225-C7D4BA50-B67C-4CB5-B9AA-B3D6BDCB88E6

Q33410225-EB48C317-A1F6-42E4-8747-D91FE357A7C3

Q33410225-EE7F93BB-8213-4D1F-965A-179DDA54183A

P304

Q33410225-49D53D4C-B3E8-4C62-A9C1-1A6F2F3858AE

P31

Q33410225-88A300CB-8E4C-488B-9547-C3B21017BC3D

P356

Q33410225-4242CA37-FC0F-467C-A2FA-108BFEB444A3

P407

Q33410225-5F72671B-FA70-4902-96B8-8A87B02C743B

P433

Q33410225-17CE4458-FA2D-4819-BC23-0CCBE64E7B66

P478

Q33410225-3B3B817D-419D-4C37-B2FD-48EA1F69002B

P50

Q33410225-682F9F3E-4F47-46D9-BEFC-2749F8F18772

Q33410225-9A2B40E5-8CF0-433A-A9E6-5B2193E3960B

Q33410225-A49429E1-45C1-465C-A159-F21EB6B48CB3

Q33410225-E21F906E-3AD6-417C-BA05-60745D23BDC0

P577

Q33410225-94CCA0B0-B4B3-4D69-8393-397668AF231B

P698

Q33410225-A623FCA3-36F2-400C-A3E1-98D07347686C

P356

JCO.2012.46.7068

P1433

Journal of Clinical Oncology

P1476

Phase Ib study of panobinostat ...... nd refractory multiple myeloma

@en

P2093

Andreas Günther

http://www.w3.org/2001/XMLSchema#string

David Siegel

http://www.w3.org/2001/XMLSchema#string

Heather Sutherland

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

Kaushal K Mishra

http://www.w3.org/2001/XMLSchema#string

María Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

Orhan Sezer

http://www.w3.org/2001/XMLSchema#string

Priscille M Bourquelot

http://www.w3.org/2001/XMLSchema#string

Richard LeBlanc

http://www.w3.org/2001/XMLSchema#string

Song Mu

http://www.w3.org/2001/XMLSchema#string

P304

3696-3703

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2012.46.7068

http://www.w3.org/2001/XMLSchema#string

P407

P433

29

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P50

Jesus San Miguel

Kenneth C Anderson

Paul G Richardson

P577

2013-09-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24019544

http://www.w3.org/2001/XMLSchema#string